8.17
price up icon1.36%   0.11
after-market After Hours: 8.17
loading
Amneal Pharmaceuticals Inc stock is traded at $8.17, with a volume of 1.15M. It is up +1.36% in the last 24 hours and up +0.49% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$8.06
Open:
$8.08
24h Volume:
1.15M
Relative Volume:
0.68
Market Cap:
$2.56B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-12.01
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+3.29%
1M Performance:
+0.49%
6M Performance:
-6.41%
1Y Performance:
+9.81%
1-Day Range:
Value
$8.08
$8.23
1-Week Range:
Value
$7.83
$8.23
52-Week Range:
Value
$6.50
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Name
Amneal Pharmaceuticals Inc
Name
Phone
908-947-3120
Name
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Employee
5,210
Name
Twitter
@amnealpharma
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
8.17 2.53B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.75 67.73B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.70 44.38B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.97B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.14 13.73B 2.99B 1.21B 1.13B 25.06

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Goldman Buy
Feb-24-25 Upgrade JP Morgan Neutral → Overweight
Sep-06-24 Upgrade JP Morgan Underweight → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Mar-08-21 Upgrade Goldman Sell → Buy
Dec-14-20 Upgrade Barclays Equal Weight → Overweight
Dec-14-20 Upgrade Guggenheim Neutral → Buy
Jul-27-20 Initiated Goldman Sell
May-12-20 Upgrade Guggenheim Sell → Neutral
Dec-12-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19 Downgrade JP Morgan Neutral → Underweight
Nov-07-19 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-11-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-08-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19 Initiated Barclays Equal Weight
May-21-19 Upgrade Raymond James Mkt Perform → Strong Buy
Mar-20-19 Initiated SunTrust Buy
Mar-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Dec-14-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18 Downgrade SunTrust Buy → Hold
Aug-13-18 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18 Initiated Morgan Stanley Overweight
Jun-22-18 Initiated B. Riley FBR, Inc. Buy
View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

pulisher
09:40 AM

Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

09:40 AM
pulisher
06:07 AM

What institutional investors are buying Amneal Pharmaceuticals Inc. stockExceptional earning trajectories - jammulinksnews.com

06:07 AM
pulisher
03:34 AM

What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Capitalize on emerging investment opportunities - jammulinksnews.com

03:34 AM
pulisher
12:27 PM

How does Amneal Pharmaceuticals Inc. generate profit in a changing economyUnlock high-yield investment opportunities - jammulinksnews.com

12:27 PM
pulisher
Jul 27, 2025

How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Achieve rapid financial growth with expert picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why Amneal Pharmaceuticals Inc. stock attracts strong analyst attentionCapital Safe Smart Trades - metal.it

Jul 27, 2025
pulisher
Jul 26, 2025

How Amneal Pharmaceuticals Inc. stock performs during market volatilityFree Stock Selection with 300% Return - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Amneal Pharmaceuticals Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Amneal Pharmaceuticals Inc. stock priceFree Investment Community - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Amneal Pharmaceuticals Prices $600M Senior Notes Offering - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Amneal Pharmaceuticals Inc. stockFree Investment Community - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 24, 2025

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st

Jul 24, 2025
pulisher
Jul 22, 2025

Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal seeks to borrow $1.8 billion in new term loans, offers notes - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal reports 3% revenue growth in Q2, advances deleveraging By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Silicon Valley - FinancialContent

Jul 21, 2025
pulisher
Jul 18, 2025

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 16, 2025

Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com

Jul 16, 2025

Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.41
price down icon 0.71%
$14.58
price down icon 2.28%
$9.26
price down icon 1.59%
drug_manufacturers_specialty_generic RDY
$14.70
price up icon 0.20%
$133.71
price up icon 1.19%
$298.14
price down icon 2.09%
Cap:     |  Volume (24h):